La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Biophytis Gestione

Gestione criteri di controllo 4/4

Biophytis' Il CEO è Stanislas Veillet, nominato in May2015, e ha un mandato di 9.25 anni. la retribuzione annua totale è € 349.00K, composta da 71.6% di stipendio e 28.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.9% delle azioni della società, per un valore di € 30.81K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.9 anni e 4.9 anni.

Informazioni chiave

Stanislas Veillet

Amministratore delegato

€349.0k

Compenso totale

Percentuale dello stipendio del CEO	71.6%
Mandato del CEO	9.3yrs
Proprietà del CEO	0.9%
Durata media del management	4yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Stanislas Veillet rispetto agli utili di Biophytis?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	€349k	€250k	-€17m
Sep 30 2023	n/a	n/a	-€18m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€22m
Dec 31 2022	€428k	€250k	-€24m
Sep 30 2022	n/a	n/a	-€27m
Jun 30 2022	n/a	n/a	-€30m
Mar 31 2022	n/a	n/a	-€31m
Dec 31 2021	€460k	€250k	-€31m
Sep 30 2021	n/a	n/a	-€28m
Jun 30 2021	n/a	n/a	-€25m
Mar 31 2021	n/a	n/a	-€25m
Dec 31 2020	€374k	€250k	-€26m
Sep 30 2020	n/a	n/a	-€24m
Jun 30 2020	n/a	n/a	-€22m
Mar 31 2020	n/a	n/a	-€22m
Dec 31 2019	€310k	€250k	-€19m
Sep 30 2019	n/a	n/a	-€19m
Jun 30 2019	n/a	n/a	-€18m
Mar 31 2019	n/a	n/a	-€15m
Dec 31 2018	€295k	€225k	-€14m
Sep 30 2018	n/a	n/a	-€13m
Jun 30 2018	n/a	n/a	-€12m
Mar 31 2018	n/a	n/a	-€12m
Dec 31 2017	€447k	€150k	-€11m

Compensazione vs Mercato: La retribuzione totale di Stanislas ($USD 388.04K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 540.72K ).

Compensazione vs guadagni: La retribuzione di Stanislas è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Stanislas Veillet (59 yo)

9.3yrs

Mandato

€349,000

Compensazione

Mr. Stanislas Veillet, Ph D., serves as Chairman of the Board and Chief Executive Officer of Biophytis SA since May 22, 2015. Mr. Veillet is the Co-founder of Biophytis (created in 2006) and served as its...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stanislas Veillet	Chairman of the Board & CEO	9.3yrs	€349.00k	0.90% € 18.6k
Nicolas Fellmann	Chief Financial Officer	1.3yrs	Nessun dato	Nessun dato
Waly Dioh	Chief Clinical Operating Officer	4.9yrs	Nessun dato	0.0060% € 124.3
Pierre Dilda	Chief Scientific Officer	4.9yrs	Nessun dato	0.0032% € 65.0
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5yrs	Nessun dato	Nessun dato
Rob van Maanen	Chief Medical Officer	3yrs	Nessun dato	0% € 0
Edouard Bieth	Chief Business Officer	less than a year	Nessun dato	Nessun dato
Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	1.7yrs	Nessun dato	0% € 0
_ Teylan	Financial Controller	no data	Nessun dato	Nessun dato

4.0yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 6XB3 è considerato esperto (durata media dell'incarico 3.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stanislas Veillet	Chairman of the Board & CEO	9.3yrs	€349.00k	0.90% € 18.6k
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5yrs	Nessun dato	Nessun dato
Claude Allary	Independent Director	3.2yrs	€25.00k	0% € 0
Jose-Alain Sahel	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Thomas Voit	Member of Scientific Advisory Board	6.9yrs	Nessun dato	Nessun dato
Roger Fielding	Member of Scientific Advisory Board	8.3yrs	Nessun dato	Nessun dato
Jean Mariani	Chairman of Scientific Advisory Board & Director	8.4yrs	€25.00k	0% € 0
Nadine Coulm	Independent Director	9.3yrs	€25.00k	0.000060% € 1.2
Yann Meunier	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Bernard Levy	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Dennis Villareal	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Francisco Guarner	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato

5.0yrs

Durata media

69yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6XB3 sono considerati esperti (durata media dell'incarico 4.9 anni).

Biophytis Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis S.A. Announces Executive Changes

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Recent updates

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure

Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit

Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

Biophytis SA, Annual General Meeting, Jun 03, 2022

Biophytis SA Announces Chief Financial Officer Changes

Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program

Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference

Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19

Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19

Independent Director Jean Franchi has left the company

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021

Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

Biophytis SA, Annual General Meeting, Apr 26, 2021

Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos

New 90-day high: €1.67

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial

Biophytis SA Receives DMC Recommendation for Starting Recruitment for Part 2 of Its Phase 2-3 Cova Study in COVID-19

New 90-day high: €1.25

New 90-day high: €0.73

New 90-day high: €0.72

Biophytis Enrolls First Patient in Brazil in COVA, A Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure

New 90-day low: €0.40

New 90-day low: €0.51

New 90-day low - €0.63

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione